

9 April 2025

## Argent BioPharma Ltd. (Argent BioPharma or the Company)

### **Strategic Collaboration Agreement for Argent EU GMP Facility in Malta.**

#### **Highlights:**

- **Strategic collaboration granting David Trading Ltd. exclusive rights to operate RGT's Facility in Malta for 49 years.**
- **David Trading Ltd. takes full managerial and financial responsibility for operating the facility, including managerial decisions, maintenance, staffing, insurance, and permit renewals.**
- **David Trading Ltd. will continue to provide and support the production of CimetrA at cost + 25%, while expanding the facility's product portfolio upon regulatory approvals.**
- **Significant cost reduction of up to USD \$1 million annually on RGT's operational expenses, resulting in substantial operational improvement while ensuring continuous production of CimetrA.**
- **Further collaboration between the companies is being evaluated to expand production services to include both new internal products and external contract manufacturing partners.**
- **Irrevocable purchase option granted to David Trading Ltd. for 100% of the Facility Company's shares, pending regulatory approval; valued at USD \$1 million for Argent BioPharma Ltd.**


#### **RGT Australia Announces Strategic Collaboration Agreement**

Argent BioPharma Ltd. (ASX: RGT) is pleased to announce that it has entered into a binding term sheet with David Trading Ltd., establishing a strategic collaboration to operate RGT's EU-GMP facility located in Malta for a term of forty-nine (49) years.

Argent BioPharma's Malta-based manufacturing facility is a fully automated, EU-GMP-certified plant specialising in liquid dose form production dedicated to the production of CimetrA™. Commissioned in May 2023, the facility has the capacity to manufacture thousands of CimetrA™ units per day. The establishment of this facility was strongly supported by the Maltese government through multi-million dollar grants.

Under the terms of the agreement, David Trading Ltd. assumes full responsibility and financial liability for the operation of the facility, including managerial decisions, maintenance, staffing, insurance, and permit renewals, while also taking on all debts and liabilities incurred from the signing date forward. This commitment ensures that David Trading Ltd. fully controls and operates the facility without any financial burden on Argent BioPharma.

Furthermore, David Trading Ltd. will continue producing CimetrA at a cost + 25% basis, ensuring continued supply to Argent BioPharma. In addition, David Trading Ltd. will introduce additional products from its portfolio to the facility's production line upon receiving necessary regulatory approvals, aiming to transform the facility into a profitable asset.



Further collaboration between the companies is being evaluated to expand production services to include both new internal products and external contract manufacturing partners. This strategy aims to expand production capacity and generate additional revenue streams, establishing Malta as a competitive hub for pharmaceutical manufacturing.

In March 2025, Argent BioPharma entered into an agreement with Dr. Shlomo Sadoun to facilitate a commercial transaction for the facility as a Contract Manufacturing Operations (CMO) service catering to pharmaceutical companies seeking specialised, cost-effective, and boutique liquid dose manufacturing solutions within the EU. This agreement will continue to allocate CMO opportunities for the facility under David Trading Ltd operations.

The Company confirms that the proposed disposal of the Malta facility will not have a material impact on its consolidated total assets, total equity interests, revenue, or earnings before interest, tax, depreciation, and amortisation.

Additionally, David Trading Ltd. has been granted an exclusive, irrevocable option to acquire 100% of the Facility Company's shares, subject to regulatory approval from the Maltese authorities and any other applicable regulatory requirements, including the ASX listing rules. The option remains valid for 49-years under the terms of the strategic collaboration. This option, exercisable through a share swap valued at USD \$1 million for Argent BioPharma Ltd. and USD \$500,000 for David Trading Ltd., remains valid regardless of whether David Trading Ltd. chooses to exercise it or if the necessary regulatory approvals are obtained. Both parties are committed to expediting the approval process to ensure a smooth transfer. The final terms of the acquisition, including the specific number of shares to be transferred, will be detailed in a definitive purchase agreement should David Trading Ltd. elect to exercise its option and announced accordingly.

**Roby Zomer, CEO & Managing Director, Argent BioPharma Ltd:** *"This strategic collaboration marks a pivotal step forward for Argent BioPharma. By entrusting the operation of our EU-GMP facility in Malta to David Trading Ltd., we are ensuring the continued supply of CimetRA while significantly enhancing operational efficiency and profitability. This partnership not only allows us to streamline costs but also opens the door to expanded production capabilities and new revenue opportunities. We are excited about the possibilities this collaboration presents and look forward to working closely with David Trading Ltd. to build a robust and scalable manufacturing ecosystem in Malta."*

—Ends—

Authorised for release by the board of directors, for further information please contact:


**Argent BioPharma**  
Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma**  
Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma Ltd**  
Suite 1, 295 Rokeby Road  
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 [info@argentbiopharma.com](mailto:info@argentbiopharma.com)



#### **About Argent BioPharma**

Argent BioPharma Limited (ASX: RGT) is an innovative clinical-stage biopharmaceutical company specialising in neuroimmunology and advanced nanomedicine. By leveraging the Neuro-Immune Modulatory (NIM) System, Argent BioPharma's robust pipeline—including CannEpil®, CogniCann®, and Cimetra®—targets CNS disorders and immune-related conditions. With a commitment to science-driven innovation, Argent BioPharma is shaping the future of cannabinoid-based therapeutics and neuroimmune modulation.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

#### **About David Trading Ltd.**

David Trading Ltd researches, develops and manufactures novel pharma-grade cannabis products and nutraceuticals. David Trading Ltd is a vertically integrated medical cannabis research and development company specialising in pharmaceutical-grade cannabis products and drug delivery technologies.



**Argent BioPharma ltd**  
Suite 1, 295 Rokeby Road  
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 [info@argentbiopharma.com](mailto:info@argentbiopharma.com)